| Schedule of Computation of Basic and Dilutive Net Loss Per Share |
The computation of basic and dilutive net loss per share attributable to common stockholders for the three and nine months ended September 30, 2026 and 2025, are as follows: | | | Three Months Ended September 30, | | | Nine Months Ended September 30, | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Basic: | | | | | | | | | | | | | | Numerator: | | | | | | | | | | | | | | Net income (loss) attributable to common shareholders | | $ | (3,659,587 | ) | | $ | 1,375,294 | | | $ | (12,358,543 | ) | | $ | (1,736,512 | ) | | Denominator: | | | | | | | | | | | | | | | | | | Weighted-average common shares outstanding | | | 2,981,011 | | | | 2,282,245 | | | | 2,703,046 | | | | 2,016,265 | | | Net income (loss) per share – basic: | | $ | (1.16 | ) | | $ | 0.60 | | | $ | (4.47 | ) | | $ | (0.86 | ) | | Diluted: | | | | | | | | | | | | | | | | | | Numerator: | | | | | | | | | | | | | | | | | | Net income (loss) attributable to common and common equivalent shareholders | | | (3,659,587 | ) | | | 1,375,294 | | | | (12,358,543 | ) | | | (1,736,512 | ) | | Denominator: | | | | | | | | | | | | | | | | | | Weighted-average common stock outstanding | | | 3,168,308 | | | | 2,282,245 | | | | 2,766,165 | | | | 2,016,265 | | | Stock options, RSUs, warrants, Earn-Out Liability, and convertible notes outstanding to purchase shares of common stock | | | - | | | | 1,274 | | | | - | | | | - | | | Total common and common equivalent shares outstanding | | | 3,168,308 | | | | 2,283,520 | | | | 2,766,165 | | | | 2,016,265 | | | Net income (loss) per share – diluted: | | $ | (1.16 | ) | | $ | 0.60 | | | $ | (4.47 | ) | | $ | (0.86 | ) |
|
| Schedule of Net Loss Per Share-Diluted Including Anti-Dilutive |
The weighted average potential shares of common stock that were excluded from the calculation of net loss per share-diluted for the periods presented because including them would have been anti-dilutive consisted of the following: | | | Three Months Ended September 30, | | | Nine Months Ended September 30, | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Stock options outstanding to purchase shares of common stock and RSUs | | | 415,577 | | | | 222,684 | | | | 395,249 | | | | 214,974 | | | Public Warrants | | | 319,216 | | | | 319,216 | | | | 319,216 | | | | 319,216 | | | SPAC Private Placement Warrants | | | 262,811 | | | | 262,811 | | | | 262,811 | | | | 262,811 | | | Private Veea Warrants | | | 7,965 | | | | 7,965 | | | | 7,965 | | | | 7,965 | | | 2025 Investor Warrants | | | 459,305 | | | | 234,721 | | | | 459,305 | | | | 79,100 | | | Convertible Notes | | | 282,729 | | | | 11,667 | | | | 280,943 | | | | 6,964 | | | White Lion Warrants | | | 130,103 | | | | - | | | | 105,646 | | | | - | | | NLabs Warrants | | | 2,344,173 | | | | - | | | | 1,379,813 | | | | - | | The weighted average potential shares of common stock that were excluded from the calculation of net loss per share-diluted because the performance or market conditions associated with these awards were not met are as follows for the periods presented: | | | Three Months Ended September 30, | | | Nine Months Ended September 30, | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | Earn-Out Liability | | | 225,000 | | | | 225,000 | | | | 225,000 | | | | 225,000 | |
|